Q1 Cons. Revenue Up 16.6% YoY to Rs 39.84 Cr, Net Profit Declines 7.0% to Rs 4.67 Cr
Gennex Laboratories reported consolidated revenue from operations of Rs 39.84 Cr for Q1 FY27 (quarter ended June 30, 2026), an increase of 16.57% YoY compared to Rs 34.18 Cr in Q1 FY26, though down 34.64% QoQ from Rs 60.96 Cr. Consolidated net profit for the quarter stood at Rs 4.67 Cr, down 6.98% YoY from Rs 5.02 Cr in Q1 FY26 and up 4.66% QoQ from Rs 4.46 Cr. Basic EPS for the quarter was reported at Rs 0.192 compared to Rs 0.217 in the year-ago period. Standalone sales were driven primarily by the domestic market at Rs 25.37 Cr, followed by export markets led by Colombia (Rs 3.51 Cr) and Egypt (Rs 2.54 Cr).
உச்சம் நம்பிக்கை
என்ன மாறியதுGennex Laboratories reported its unaudited standalone and consolidated Q1 FY27 financial results showing YoY top-line growth but lower net profitability.
ஏன் இது முக்கியம்Demonstrates moderate YoY top-line expansion in bulk drugs and intermediates, though profit margins remain compressed relative to the prior-year quarter.
Consolidated Revenue (Q1): Rs 39.84 கோடிConsolidated Net Profit (Q1): Rs 4.67 கோடிConsolidated EPS (Q1): Rs 0.192Quarterly Revenue vs TTM Revenue: ~22.5%
📅 குறுகிய காலம்Likely neutral reaction as top-line growth is offset by a slight YoY net profit contraction and sequential revenue normalization.
📈 நீண்ட காலம்Limited; operational performance depends on expanding active pharmaceutical ingredient/bulk drug volumes and sustained export market penetration.
⚠ அபாய எச்சரிக்கைகள்
- Sequential quarterly revenue volatility (fell ~34.6% QoQ from Q4 FY26).
- Geographic concentration in top export markets like Colombia and Egypt.
👀 கவனிக்க வேண்டியவை
Track sequential revenue stability over upcoming quarters and monitor operating margin trends given higher raw material and other operating costs.
